SCHEMBL9944219

SCHEMBL9944219

CCOc1c(Cl)cc(C(=O)Nc2ccc(C(C)=O)cc2)cc1OC

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAS1R3 Q7RTX0 1/20 0.55
TAS1R1 Q7RTX1 1/20 0.55
TAS1R2 Q8TE23 1/20 0.55
MAPT P10636 8/20 0.55
SMN1; SMN2 Q16637 2/20 0.55
TP53 P04637 1/20 0.55
MEN1 O00255 6/20 0.54
KMT2A Q03164 6/20 0.54
NPC1 O15118 2/20 0.54
RAB9A P51151 2/20 0.54
ALDH1A1 P00352 4/20 0.53
KDM4E B2RXH2 1/20 0.53
CYP1A2 P05177 1/20 0.53
ABCB1 P08183 1/20 0.52
GAA P10253 3/20 0.52
NPSR1 Q6W5P4 1/20 0.52
LMNA P02545 3/20 0.50
MCL1 Q07820 2/20 0.50
MAPK1 P28482 1/20 0.50
GFER P55789 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1458097 0.91 MEN1 (0.63) TAS1R3TAS1R1TAS1R2MAPTSMN1; SMN2
SCHEMBL9944170 0.90 KMT2A (0.64) TAS1R3TAS1R1TAS1R2MAPTSMN1; SMN2
SCHEMBL9944220 0.89 MAPT (0.53) TAS1R3TAS1R1TAS1R2MAPTSMN1; SMN2
SCHEMBL9944214 0.89 MEN1 (0.52) TAS1R3TAS1R1TAS1R2MAPTSMN1; SMN2
SCHEMBL9944293 0.86 TAS1R3 (0.53) TAS1R3TAS1R1TAS1R2MAPTSMN1; SMN2
SCHEMBL9944194 0.86 KMT2A (0.56) TAS1R3TAS1R1TAS1R2MAPTSMN1; SMN2
SCHEMBL9944224 0.85 MAPT (0.52) TAS1R3TAS1R1TAS1R2MAPTSMN1; SMN2
SCHEMBL9944216 0.85 TAS1R3 (0.56) TAS1R3TAS1R1TAS1R2MAPTSMN1; SMN2
SCHEMBL9944222 0.84 GAA (0.53) TAS1R3TAS1R1TAS1R2MAPTSMN1; SMN2
SCHEMBL9944223 0.84 MAPT (0.48) TAS1R3TAS1R1TAS1R2MAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120149737-A1 Therapeutic Aryl-Amido-Aryl Compounds and Their Use KING'S COLLEGE LONDON (GB) 2012-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120149737-A1 Therapeutic Aryl-Amido-Aryl Compounds and Their Use RARA, RARB, RARG TAS1R3 1123/4885TAS1R1 693/4885TAS1R2 808/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.